St Anne’s is the home of choice for the brightest and most ambitious students, including those from underrepresented groups.
St Anne’s is one of Oxford’s largest colleges, with over 800 students. Our Fellows’ world leading research ranges across the arts, humanities, social sciences, mathematics, and physical, life and medical sciences.
Our diverse, inclusive community extends around the globe through our alumnae, who build on their experiences here to change the world for the better.
Situated within 5 acres of tranquil leafy grounds, St Anne’s enjoys a unique atmosphere in which to hold any conference, dinner or special event.
Professorial Fellow in Medical SciencesProfessor of Haematology, Weatherall Institute of Molecular MedicineConsultant HaematologistGroup Leader MRC Molecular Haematology Unit
Email:paresh.vyas@imm.ox.ac.uk
Paresh Vyas is Professor of Haematology at the University of Oxford. He studied medicine at Cambridge then Oxford. After completing his medical and haematology training in London, he did his PhD with Professor Doug Higgs and Professor Sir David Weatherall at the MRC Molecular Haematology Unit, Oxford. A three-year post-doctoral fellowship with Professor Stuart Orkin at Harvard University followed. He is a research-active Consultant Haematologist with a clinical practice in myeloid disorders: myelodysplastic syndrome, MDS, acute myeloid leukaemia, AML, and myeloproliferative disorders, MPD, as well as allogeneic stem cell transplant.
His research in the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid stem cells. He studies single cell biology in normal and leukaemic haemopoiesis. He is on the UK AML and MDS clinical trial groups. He is co-Lead of the Oxford BRC Haematology and Stem Cells Theme, is on the Board of NHSBT, vice-chair of the MRC Clinical Training Panel and Translational Lead for the UK Therapy Acceleration Program.
Quek, L., David, M.D., Kennedy, A. et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med 24, 1167–1177 (2018). https://doi.org/10.1038/s41591-018-0115-6
Karamitros, D., Stoilova, B., Aboukhalil, Z. et al. Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells. Nat Immunol 19, 85–97 (2018). https://doi.org/10.1038/s41590-017-0001-2
Lynn Quek, Georg W. Otto, Catherine Garnett, et al. Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med 25 July 2016; 213 (8): 1513–1535. doi: https://doi.org/10.1084/jem.20151775